Immune Defense Protein Impact On Respiratory Immune Outcomes (NCT07431840) | Clinical Trial Compass
RecruitingNot Applicable
Immune Defense Protein Impact On Respiratory Immune Outcomes
United States300 participantsStarted 2025-12-05
Plain-language summary
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
Who can participate
Age range60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 60 years and older
✓. Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
✓. Able to read and understand English.
✓. Able to read, understand, and provide informed consent.
✓. Able to use a personal smartphone device and download Chloe by People Science.
✓. Able to receive shipment of the product at an address within the United States.
Exclusion criteria
✕. Do not have a personal smartphone, internet access, or unwilling to download Chloe.
✕. Already in an immunocompromised state, including:
✕. Other Concomitant Conditions and Therapies:
✕. Any investigational therapies or treatments within 30 days prior to enrollment.
✕. Known diagnosis of Asthma and/or COPD
✕. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
✕. Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes
✕
What they're measuring
1
Impact on Upper Respiratory Symptom Incidence, Duration and Severity
. Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes